Initial characterization of an immunotoxin constructed from domains II and III of cholera exotoxin.
Immunotoxins are antibody-toxin fusion proteins under development as cancer therapeutics. In early clinical trials, immunotoxins constructed with domains II and III of Pseudomonas exotoxin (termed PE38), have produced a high rate of complete remissions in Hairy Cell Leukemia and objective responses in other malignancies. Cholera exotoxin (also known as cholix toxin) has a very similar three-dimensional structure to Pseudomonas exotoxin (PE) and when domains II and III of each are compared at the primary sequence level, they are 36% identical and 50% similar. Here we report on the construction and activity of an immunotoxin made with domains II and III of cholera exotoxin (here termed CET40). In cell viability assays, the CET40 immunotoxin was equipotent to tenfold less active compared to a PE-based immunotoxin made with the same single-chain Fv. A major limitation of toxin-based immunotoxins is the development of neutralizing antibodies to the toxin portion of the immunotoxin. Because of structure and sequence similarities, we evaluated a CET40 immunotoxin for the presence of PE-related epitopes. In western blots, three-of-three anti-PE antibody preparations failed to react with the CET40 immunotoxin. More importantly, in neutralization studies neither these antibodies nor those from patients with neutralizing titers to PE38, neutralized the CET40-immunotoxin. We propose that the use of modular components such as antibody Fvs and toxin domains will allow a greater flexibility in how these agents are designed and deployed including the sequential administration of a second immunotoxin after patients have developed neutralizing antibodies to the first.
Sarnovsky
Robert
R
Laboratory of Molecular Biology, CCR, NCI, NIH, HHS, Bethesda, MD 20892, USA.
Tendler
Tara
T
Makowski
Matheusz
M
Kiley
Maureen
M
Antignani
Antonella
A
Traini
Roberta
R
Zhang
Jingli
J
Hassan
Raffit
R
FitzGerald
David J
DJ
D000595:Amino Acid Sequence; D000818:Animals; D057134:Antibodies, Neutralizing / Q000097:blood / Q000276:immunology; D001483:Base Sequence; D015153:Blotting, Western; D002772:Cholera Toxin / Q000235:genetics / Q000276:immunology*; D003429:Cross Reactions; D005098:Exotoxins / Q000276:immunology; D006801:Humans; D000922:Immunotoxins / Q000235:genetics / Q000276:immunology*; D008969:Molecular Sequence Data; D009369:Neoplasms / Q000097:blood / Q000276:immunology; D011549:Pseudomonas / Q000276:immunology; D011990:Receptors, Transferrin / Q000276:immunology; D011993:Recombinant Fusion Proteins / Q000235:genetics; D057127:Single-Chain Antibodies / Q000276:immunology
D057134:Antibodies, Neutralizing; D005098:Exotoxins; D000922:Immunotoxins; D011990:Receptors, Transferrin; D011993:Recombinant Fusion Proteins; D057127:Single-Chain Antibodies; D002772:Cholera Toxin